Literature DB >> 28679092

Master Protocols to Study Multiple Therapies, Multiple Diseases, or Both.

Janet Woodcock1, Lisa M LaVange1.   

Abstract

Mesh：

Year:  2017        PMID： 28679092     DOI： 10.1056/NEJMra1510062

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  191 in total

Review 1.  Histology-agnostic drug development - considering issues beyond the tissue.

Authors:  Roberto Carmagnani Pestana; Shiraj Sen; Brian P Hobbs; David S Hong
Journal:  Nat Rev Clin Oncol       Date:  2020-06-11       Impact factor: 66.675

Review 2.  Do immune checkpoint inhibitors need new studies methodology?

Authors:  Roberto Ferrara; Sara Pilotto; Mario Caccese; Giulia Grizzi; Isabella Sperduti; Diana Giannarelli; Michele Milella; Benjamin Besse; Giampaolo Tortora; Emilio Bria
Journal:  J Thorac Dis       Date:  2018-05       Impact factor: 2.895

3.  To randomize, or not to randomize, that is the question: using data from prior clinical trials to guide future designs.

Authors:  Alyssa M Vanderbeek; Steffen Ventz; Rifaquat Rahman; Geoffrey Fell; Timothy F Cloughesy; Patrick Y Wen; Lorenzo Trippa; Brian M Alexander
Journal:  Neuro Oncol       Date:  2019-10-09       Impact factor: 12.300

4.  The Landmark Series: Preoperative Therapy for Pancreatic Cancer.

Authors:  Sameer H Patel; Matthew H G Katz; Syed A Ahmad
Journal:  Ann Surg Oncol       Date:  2021-05-28       Impact factor: 5.344

5.  Reply to Voelkel and Newman: The Light at the End of the Long Pulmonary Hypertension Tunnel Brightens.

Authors:  Jason M Elinoff; Marc Humbert; Michael A Solomon
Journal:  Am J Respir Crit Care Med       Date:  2018-09-15       Impact factor: 21.405

6.  Implementing Optimal Designs for Dose-Response Studies Through Adaptive Randomization for a Small Population Group.

Authors:  Yevgen Ryeznik; Oleksandr Sverdlov; Andrew C Hooker
Journal:  AAPS J       Date:  2018-07-19       Impact factor: 4.009

7.  Advancing Chronic Obstructive Pulmonary Disease Therapy: Opportunities, Challenges, and Excitement.

Authors:  Stephen I Rennard
Journal:  Am J Respir Cell Mol Biol       Date:  2019-01       Impact factor: 6.914

8.  A platform for efficient early evaluation of biomarker-associated therapies in newly diagnosed IDH wild-type, MGMT unmethylated glioblastoma.

Authors:  Howard Colman
Journal:  Neuro Oncol       Date:  2019-01-01       Impact factor: 12.300

9.  TOP: Time-to-Event Bayesian Optimal Phase II Trial Design for Cancer Immunotherapy.

Authors:  Ruitao Lin; Robert L Coleman; Ying Yuan
Journal:  J Natl Cancer Inst       Date:  2020-01-01       Impact factor: 13.506

Review 10.  Moving towards a molecular taxonomy of autoimmune rheumatic diseases.

Authors:  Guillermo Barturen; Lorenzo Beretta; Ricard Cervera; Ronald Van Vollenhoven; Marta E Alarcón-Riquelme
Journal:  Nat Rev Rheumatol       Date:  2018-01-24       Impact factor: 20.543
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.